Who founded NephroDI?

NephroDI was founded by Jeff M. Sands, M.D., Jeff M. Sands, Janet D. Klein.

Who are NephroDI's investors?

NephroDI's investors include Sound Bioventures.

How much funding has NephroDI raised?

NephroDI has disclosed $3.6M raised across 2 rounds.

Where is NephroDI headquartered?

NephroDI is headquartered in Seattle, US.

NephroDI

Seattle, US · Delaware corporation · 1 known investors

Find your way into NephroDI

Paths you didn't know you had: your email and LinkedIn already hold routes to the NephroDI team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Nephrodi is a biotechnology company developing treatments for kidney conditions, including the rare disease Nephrogenic Diabetes Insipidus (NDI). Its work centers on renal physiology research and translating it toward clinical products.

Biotech Healthtech Medical Devices

Founders & leadership

Jeff M. Sands, M.D.Co-founder

Jeff M. SandsChief Medical Officer & Founder

Janet D. KleinDirector of Biology & Founder

Rachael Hagan President & Chief Executive OfficerRachael Hagan is President and CEO of NephroDI, a biotechnology company developing treatments for kidney conditions including Nephrogenic Diabetes Insipidus. She has held healthcare technology and executive roles involving strategic planning and cross-functional team management.

Fred CalloriNamed on SEC filing

Donna SeeNamed on SEC filing

Khanna

Pillarisetti

Board

Chris GarabedianBoard director

Investors · 1

Sound Bioventureslisted by Sound BioventuresMalmö

How we know: Sound Bioventures's portfolio page · funding news · biolocity.gatech.edu · the VCSheet dataset · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$3.6M disclosed across 2 rounds · 2021–2024

▶$2MraisedJun 2024 · 2 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Rachael HaganExecutive Officer, Director
Michael GrissingerDirector
Bibhash MukhopadhyayDirector
Jeff M. Sands, M.D.Executive Officer

Offering amount: $4M
Amount sold: $2M
Proceeds to insiders: $2.1M
First sale: Jun 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1.6MraisedFeb 2021 · 1 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Fred CalloriDirector
Chris GarabedianDirector
Donna SeeDirector
Jeff M. Sands, M.D.Executive Officer
Rachael HaganExecutive Officer, Director

Offering amount: $1.6M
Amount sold: $1.6M
First sale: Feb 2021
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

NephrogenNephrogen develops AI-powered AAV delivery vehicles for genetic medicines targeting kidney and pancreatic diseases. The company uses high-throughput in vivo screening to design tissue-specific viral vectors that are significantly more efficient and less immunogenic than existing alternatives.

Viridian TherapeuticsViridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit. The company focuses on clinical development and patient support programs in the biotech sector.

Novo NordiskNovo Nordisk is a pharmaceutical company that develops and markets treatments for conditions including diabetes, obesity/weight management, and haemophilia, with products such as GLP-1 therapies. It serves patients and healthcare markets globally.

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies working in the same space as NephroDI.

In the news

NephroDI Therapeutics Funding: $3.6M | Complete Analysis | Extruct AIextruct.ai

Frequently asked questions

What does NephroDI do?: Nephrodi is a biotechnology company developing treatments for kidney conditions, including the rare disease Nephrogenic Diabetes Insipidus (NDI). Its work centers on renal physiology research and translating it toward clinical products.
Who founded NephroDI?: NephroDI was founded by Jeff M. Sands, M.D., Jeff M. Sands, Janet D. Klein.
Who are NephroDI's investors?: NephroDI's investors include Sound Bioventures.
How much funding has NephroDI raised?: NephroDI has disclosed $3.6M raised across 2 rounds.
Where is NephroDI headquartered?: NephroDI is headquartered in Seattle, US.